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Abstract
An increasing number of cancer patients have found new hope in the form of recently discovered cell 
immunotherapies. These novel treatments empower our own immune system to fight and eradicate 
the malignant tumours, even in metastatic stages. Unprecedented outcomes have been demonstrated 
with bioengineered cells especially modified in laboratories to trigger a highly specific and active 
anti-tumour function; however, a main bottleneck for the implementation of these promising 
therapies resides in the old-fashioned and limited techniques employed for the in vitro analysis and 
study of cells during manufacturing and testing processes. Optical label-free biosensors are currently 
arising as promising analytical technologies for a simplified and accurate cell analysis. In particular, 
biosensors based on evanescent field principles enable direct, non-invasive, and real-time monitoring 
of biological events, showing outstanding sensitivities and excellent robustness. Furthermore, these 
biosensors are easily incorporated in lab-on-a-chip platforms for simple operation and implementation 
in clinical laboratories. In this review, the authors present and discuss the more recent research 
aimed to develop label-free optical biosensors for the analysis of live cells and the direct benefits 
offered to cell immunotherapy production allowing for its widespread implementation.
THE REVOLUTION OF CANCER 
IMMUNOTHERAPIES 
Cancer immunotherapy has been profiled as one 
of the major breakthroughs of the decade and 
will probably remain a paramount biomedical 
landmark in decades to come. While it has 
long been a pursued goal in immunology and 
oncology, only now are the first clinical trials 
showing significant and impressive results in 
the treatment of cancer patients.1 This relatively 
new therapy seeks the activation, inhibition, 
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or improvement of the immune system to fight 
cancer. Instead of directly targeting tumour 
cells, such as conventional radiation therapy 
or chemotherapy, immunotherapy approaches 
empower the patient’s natural immune system 
to attack them. Therefore, the benefits promised 
by cancer immunotherapies include not only a 
remarkable increase of treatment efficiencies, 
but also fewer side effects, and the possibility to 
treat certain cancer types that do not respond to 
other therapies or are in advanced stages.
Immunotherapy strategies can be categorised 
into three broad groups: passive 
immunomodulation, active immunisation (i.e., 
cancer vaccines), and the adoptive cell transfer 
approaches. The first passive immunomodulatory 
treatments were approved by the U.S. Food and 
Drug Administration (FDA) in the 1990s and are 
widely available for cancer patients. This type of 
immunotherapy consists of the administration 
of cytokines and other molecules that boost 
the general immune response of the body to 
attack the malignant cells. Among them, the 
administration of IL-2, a T cell growth factor, is 
used to stimulate endogenous tumour-reactive 
cells in vivo and has shown reproducible 
regression of solid human cancers. More recently, a 
new immunomodulatory approach has emerged, 
which makes use of monoclonal antibodies to 
inhibit the immune checkpoints that prevent T 
cells to identify and eliminate the tumour cells.2 
The blockade of specific checkpoint molecules, 
such as cytotoxic T-lymphocyte-associated 4 
(CTLA4) or programmed-death 1 (PD1), have 
shown impressive results for the treatment of 
different malignancies, such as bladder cancer, 
non-small cell lung cancer, and cutaneous 
melanoma. In fact, the innovation of these 
approaches was awarded with the Nobel Prize 
in Medicine in 2018. However, because these 
drugs interfere with the patient immune system 
in a non-specific manner, the treatment is far 
from reaching optimum efficacy and probably 
causes severe side effects. 
Instead, a more active immunotherapy could 
provide better outcomes. Therapeutic cancer 
vaccines are generally intended to treat growing 
tumours by strengthening the immune response 
of the patient to selectively attack the malignant 
cells.3 For that purpose, the vaccines are 
designed to activate the T cells by presenting 
specific tumour-associated antigens, which are 
proteins or peptides solely or over-expressed in 
cancer cells. Several vaccination strategies are 
currently under development or being evaluated 
in clinical and preclinical trials, including protein 
and peptide vaccines, genetic vaccines (DNA, 
RNA, and viral), and cell vaccines (tumour or 
immune cells). This therapeutic immunisation 
has demonstrated minimal toxicity in all clinical 
studies and also offers a long-lasting protection 
against tumour appearance and progression. The 
main challenge to cancer vaccines relies on the 
immunosuppressive tumour microenvironment 
that prevents the immune cells to act and 
proliferate and, therefore, suggests that vaccines 
should be administered in combination with other 
agents or approaches to synergistically engage 
the anti-tumour response.
Finally, one of the most attractive and 
encouraging immunotherapies is the so-called 
adoptive cell therapy.4 This strategy consists 
of identifying and/or engineering the patient’s 
own T lymphocytes to enhance the anti-tumour 
activity, expand them ex vivo, and reinfuse them 
again into the patient with cancer (Figure 1). 
The massive transfer of these powerful cells into 
the patient’s body has demonstrated an almost 
immediate tumour regression and eradication 
while offering a long-lasting protection against 
cancer recurrence. Furthermore, because the 
treatment employs the patient’s own cells, 
the associated side effects and toxicity could 
be minimal. 
This article briefly reviews the current biomedical 
challenges associated with cell immunotherapies, 
especially during the production and 
evaluation processes, and how they can limit 
their widespread administration to cancer 
patients. The authors also introduce optical 
biosensor nanotechnologies as pioneering and 
powerful platforms to boost and facilitate the 
manufacturing and implementation of such 
personalised medicine, enabling a highly 
accurate, faster, and simpler analysis of live cells 
and immune system activity.
CELL IMMUNOTHERAPIES: PROMISES 
AND CHALLENGES
There are two main types of cell-based 
immunotherapies depending on whether they 
use the patient’s own tumour infiltrating 
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lymphocytes (TIL) or artificially bioengineered T 
cells carrying a chimeric antigen receptor (CAR) 
on the cell surface.
Autologous TIL are immune cells that have 
recognised and infiltrated the tumour to 
eradicate it but have been inactivated by 
the effect of the tumour microenvironment 
and cancer immunosuppressive strategies. 
These lymphocytes can be extracted from 
the tumour peripheral blood, expanded 
ex vivo, and stimulated to reinforce their anti-
tumour immune activity.5 Prior to reinfusion, the 
patient undergoes a previous lymphodepletion 
procedure to eliminate endogenous lymphocytes 
that can compete with activated TIL. Additionally, 
the cell transfer is usually aided by co-adjuvants, 
such as IL-2, to enhance the anti-tumour 
performance. The adoptive TIL therapy has 
so far demonstrated outstanding response 
rates in melanoma, even in metastatic stages. 
Ongoing trials for breast, ovarian, or colorectal 
cancer are showing promising results when 
combined with costimulatory ligands or other 
immunotherapeutic strategies; however, the 
broad applicability of TIL therapy is limited 
because not all tumours yield to immunologically 
active T cells and not all cancer patients have 
TIL. Identifying antigen-specific T cells with 
effective anti-tumour function in blood samples 
is an arduous task in clinical and biomedical 
laboratories. Another important limitation 
relates to the manufacturing process of the 
therapy. TIL are usually grown with multiple 
rounds of expansion using cytokines or other 
stimuli, and it has been shown that their immune 
activity and anti-tumour efficiency is seriously 
reduced after the long-term ex vivo cultures. 
5. Re-infusion
into the patient
1. Blood extraction and T 
cell isolation
2. T cell activation by 
genetic modification
4. In vitro cloning and 
expansion
Analysis of anti-tumour 
activity and specificity
Figure 1. Schematic representation of the production process of cell immunotherapies based on adoptive  
cell transfer.
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Reducing the number of expansion cycles during 
therapy production is a key factor to enhance 
the final effectivity and performance of the 
immune treatment. 
An alternative strategy is providing the most 
exciting results for cell immunotherapies. In the 
so-called ‘CAR-T’ cell therapy, T lymphocytes from 
the patients are modified with artificial surface 
receptors (i.e., CAR) that consist of an antibody-
derived ligand fused with the T cell receptor 
signalling machinery.6 A CAR moiety therefore 
combines a specific antigen binding domain that 
confers recognition of a tumour-specific antigen, 
with intracellular signalling motifs that promote 
T cell activation. The main advantage of CAR-T 
cell therapy in comparison with the TIL strategy 
is that the CAR-T cells can be bioengineered and 
produced from a small number of T lymphocytes, 
independently of their native anti-tumour avidity. 
Two of these immunotherapies have been 
already approved by the FDA for treating blood 
cancers (i.e., acute lymphoblastic leukaemia and 
aggressive B-cell non-Hodgkin lymphoma). The 
European Medicines Agency (EMA) has also 
started the approval procedure for these CAR-T 
cell therapies. In parallel, many laboratories 
worldwide are intensively working on developing, 
optimising, and evaluating new CAR-T cell 
therapies for attacking solid tumours; however, 
relevant success has not yet been accomplished, 
probably due to the multiple immunosuppressive 
mechanisms that T cells find within the tumour 
microenvironment. As well as this, CAR-T cell 
therapy has been associated with cytokine 
release syndrome in patients. The rapid activation 
and expansion of these T cells upon infusion 
may trigger an immune system reaction that 
can yield to fever, organ dysfunction, neurologic 
symptoms, and other toxicities. To manage these 
serious side effects, the use of corticosteroids 
or cytokine receptor blockers along with the 
immunotherapy is being tested, with promising 
results so far.
Beyond the particular biomedical challenges, 
cell immunotherapies need to face 
important obstacles that hamper their 
widespread implementation and administration.7,8 
The manufacturing and evaluation process of 
cell immunotherapies involves multiple and 
highly specialised procedures, including labour-
intensive cultures and routine performance of cell 
analyses to verify immune responses and anti-
tumour activity before re-infusion into the patient 
(Figure 1). Currently, the analysis of the live cell 
functionality in clinical and research laboratories 
is based on fluorescent or colorimetric 
techniques, such as flow cytometry and 
enzyme-linked immunosorbent assays (ELISA). 
These methodologies have demonstrated 
outstanding sensitivities for analysing and sorting 
cell phenotypes according to protein expression 
and secretion; however, they experience 
important constraints in terms of automation, 
time resolution, cost efficiency, and cell viability. 
The need for fluorescent and colorimetric 
labels for the detection not only compromises 
cell activity and recovery after the study, but 
also limits the analysis to endpoint results and 
impedes the integration in appropriate culture 
environments. Techniques such as flow cytometry 
require initial large amounts of cells, which usually 
imply previous in vitro expansion procedures 
that reduce the eventual anti-tumour efficiency 
of the cells and inevitably delay the therapy 
administration to the patient.
Herein, the introduction of optical biosensor 
nanotechnologies to the field of cell analysis 
could bring an opportunity for accelerating the 
production process of cell immunotherapies, 
improving the evaluation accuracies, and also 
reducing the final costs of the treatment.
OPTICAL BIOSENSORS FOR LABEL-
FREE AND REAL-TIME ANALYSIS
Optical biosensors exploit the electromagnetic 
properties of light for the detection, 
quantification, and analysis of biochemical 
interactions with a high sensitivity, and with 
capabilities for label-free and real-time format 
assays.9,10 Optical label-free biosensors are 
generally based on the evanescent wave 
techniques, which enables the detection of minute 
refractive index variations caused by changes of 
mass within an evanescent electromagnetic field 
that is generated at the interface between the 
sensor and the sample (100–500 nm). The two 
most common configurations are the surface 
plasmon resonance (SPR)-based biosensors 
and the waveguide-based technologies, such 
as resonators or interferometers (Figure 2). SPR 
systems employ a nanometre thin layer of gold 
(45–50 nm) as sensor surface. Upon illumination 
at certain angle and wavelength, the free 
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electrons of the metal start oscillating collectively 
creating the so-called plasmon resonance, 
which in turn generates an evanescent wave 
that penetrates in the dielectric medium and 
propagates a small distance along the surface. 
The plasmon resonance is characterised by the 
appearance of an absorption dip in the reflected 
light. By measuring variations in the angle, 
wavelength, or intensity of the SPR dip, it is possible 
to monitor in real time biological events occurring 
on the sensor surface.11 SPR biosensors are 
widely commercially available and are employed 
in many research laboratories and pharmaceutical 
industries to carry out routine analysis of 
biomolecular interactions, kinetic analysis, or drug 
discovery and evaluation assays.11–14 Accompanied 
by the progress in nanotechnology in the last 
decade, more sophisticated versions of plasmonic 
biosensors have appeared and exponentially 
arose. Nanoplasmonic biosensors incorporate 
nanostructured surfaces such as nanodiscs, 
nanorods, nanoslits, and nanoholes that exhibit a 
localised surface plasmon resonance and provide 
exceptional features that can be translated in 
enhanced sensitivities, multiplexing capabilities, 
or higher miniaturisation and integration 
adaptability.10,15,16 On the other hand, waveguide-
based technologies are based on the leaky 
electromagnetic mode of light travelling along 
a waveguide material. The resonant waveguide 
grating (RWG) biosensors are commonly used 
and commercially available. In this platform, 
the light is coupled to a waveguide via grating 
structures, where it propagates through 
generating an evanescent field and resulting 
in a narrowband of reflected or transmitted 
wavelengths detected at the output.17 RWG 
biosensors have been successfully integrated in 
A) Surface plasmon resonance biosensor 
C) Resonant waveguide grating biosensor D) Waveguide interometer biosensors 
Evanescent field











Detector DetectorLight source Light source
B) Nanoplasmonic biosensors
Figure 2: (A) Illustration of a surface plasmon resonance biosensor working in prism-coupling configuration. (B) 
Illustration of a localised surface plasmon resonance biosensor working in prism-coupling configuration. Right 
panels show scanning electron microscopy images of different nanoplasmonic structures. (C) Illustration of a 
resonant waveguide grating biosensor in angular configuration. (D) Illustration of a waveguide  
interferometer biosensor.
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multiwell plates and imaging configuration for 
high-throughput and multiplexed screening.18 
In parallel to RWG systems, waveguide-based 
interferometers have also been realised, 
achieving outstanding sensitivities for label-
free detection. Here, the measuring guided 
light mode, in contact with the sample, is 
combined to a reference light creating an 
interference. The differences in phase are used 
to detect and quantify biochemical interactions 
occurring at the sensor area.19 Some examples 
of waveguide-based sensors are the well-known 
Mach-Zehnder interferometers,20 the bimodal 
waveguide interferometers,21 or the grating-
coupled interferometers.22
Over the last years, there has been a steady 
increase in the number of scientific publications 
and patents in the area of optical label-free 
biosensors for the detection of numerous 
molecules or pathogens, such as bacteria, 
viruses, DNA or RNA, proteins, peptides, or small 
molecules like drugs or neurotransmitters.10,11,19,23 
Surprisingly, the application of optical label-free 
platforms for live cell biology remains relatively 
unexplored.24,25  The predominate challenges 
are related to the lack of an appropriate 
biochemical design for providing clinically relevant 
information; the use of conventional microfluidic 
systems being unsuitable for cell culture and 
long-term analysis; and the inherent limitations 
of mass-related sensing of optical label-free 
methods, which commonly yields to insufficient 
sensitivity for small biomolecule detection and 
selectivity issues when evaluating complex 
fluids, such as culture media or blood serum 
and plasma. Nevertheless, a few studies have 
investigated the use of label-free optical sensing 
technology for the analysis of cell functionality 
in real time, showing promising potential, 
especially for the implementation in cell 
immunotherapy development. 
OPTICAL LABEL-FREE  
BIOSENSORS FOR CELL  
IMMUNOTHERAPY APPLICATIONS
Two critical steps in the cell immunotherapy 
development process could be greatly improved 
with the introduction of optical sensing 
technologies: the detection and identification 
of relevant immune cells from human samples, 
and the evaluation of the immune cell activity 
and tumour response. The high sensitivity, label-
free format, and real-time analysis capabilities of 
optical biosensors might enable the rapid isolation 
of specific T lymphocytes with anti-tumour 
reactivity directly from tumour peripheral blood 
samples, without the need for previous expansion 
steps and avoiding cell staining with fluorescent 
markers. On the other hand, retrieving real-time 
and quantitative information of cell activity 
events, such as membrane receptor activity or 
protein secretion, provides direct insights in cell 
status and functionality. 
For example, cancer cells secrete cytokines to 
the tumour microenvironment in order to grow 
and proliferate, or to inhibit the action of immune 
cells trying to attack them. Likewise, immune 
T cells can release different types of proteins 
(e.g., cytokines, interferons, necrosis factors, and 
enzymes) for either killing tumour cells or as a 
signalling tool for recruiting other immune cells 
and enhancing the immune response. Thus, 
the label-free and real-time analysis of cell 
secretion can facilitate the evaluation of immune 
cell activation upon interaction with tumour 
antigens, the cancer cell response, or the study 
of immunosuppressive strategies in tumour 
microenvironments (Figure 3A). For the study of 
cancer cell activity and tumour progression, Liu 
et al.26 developed a SPR biosensor able to monitor, 
in real time, the secretion of vascular endothelial 
growth factor (VEGF), a cytokine responsible for 
promoting the formation of blood vessels and 
tumour spread. The SPR system incorporated a 
mini cell culture module within the microfluidics 
that was placed close to the sensor surface. 
Ovarian carcinoma cells were stimulated with 
a calcium ionophore and the secretion of VEGF 
was readily detected by specific antibodies 
immobilised on the sensor surface. Li et al.27 
developed a more advanced lab-on-a-chip 
nanoplasmonic system for VEGF secretion 
analysis from live HeLa cells. The platform 
consisted of two interconnected modules: a 
microfluidic cell module, where cells could be 
cultured with appropriate temperature and 
humidity conditions, and the optical sensor 
module based on gold nanohole arrays. The 
nanoplasmonic sensor with multiplexing 
adaptability monitored the culture cell 
supernatant for up to 10 hours and was able 
to detect VEGF secretion from cancer cells at 
approximately 6 hours after stimulation.
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For the analysis of immune cell activity, some 
promising approaches have also been proposed. 
Oh et al.28 demonstrated for the first time the 
detection of cytokine secretion from immune T 
cells directly isolated from human blood. Their 
system was based on a nanoplasmonic surface 
surrounded by a microfluidic cell chamber 
only separated by a micropillar array. After cell 
incubation and stimulation, they could monitor 
the detection of TNF-α directly secreted by CD45 
cells. With this platform, they could perform a 
cellular function immunoanalysis with minimal 
blood sample volume (3 µL) and a total assay 
time three times shorter than conventional 
ELISA. Later, the same group demonstrated 
the multiplexed analysis of different cytokines 
(IL-2, IFN-γ, and TNF-α) employing a gold 
nanorod-based biosensor.29 Although in this 
system the cells were not cultured in situ, 
they proved the potential of nanoplasmonic 
biosensors for immune cell profiling in a rapid 
and accurate mode. Pursuing the sensitivity 
limits of nanoplasmonics, researchers have also 
attempted single-cell secretion analysis. Raphael 
et al.30 developed a gold nanodisc biosensor 
and showed real-time detection of antibody 
secretion directly from an individual hybridoma 
cell. More recently, Li et al.31 employed a gold 
nanohole array sensor integrated with a valve-
gated microfluidic chamber to monitor IL-2 
secretion from isolated T cells. The optofluidic 
system enabled not only the ultrasensitive 
detection of the cytokine secretion, but also the 
spatio-temporal profiling of the secretion event, 
revealing large heterogeneity and behaviour 
differences between various cells from the same 
cell line.
Another approach for elucidating cell activity is 
by measuring the triggering of membrane 
receptor signalling. When live cells are placed 
on the sensor surface, the evanescent field is 
able to probe changes of mass distribution 
inside the cytosol of the cell (i.e., dynamic 
mass redistribution), such as those occurring 
when the signalling is activated (Figure 3B). 
This strategy, however, requires the evanescent 
field to propagate over large areas ensuring 
maximum coverage of the cell entity; therefore, 
waveguide-based biosensors are better suited 
for this application. Fang et al.32,33 employed a 
RWG biosensor with angular modulation to 
monitor the EGF-receptor activation in cancer 
cells. Upon stimulation with EGF molecules, they 
were able to detect mass redistribution inside 
living cells in real time, which was attributed to 
the molecular rearrangements in the cell during 
the signalling cascade; however, because EFG 
Figure 3: Conceptual illustrations of different cell assays performed with optical label-free biosensors.
(A) Detection of protein secretion; (B) Detection of cytosolic dynamic mass redistribution (DMR); (C) Detection and 
capture of specific anti-tumour cells.
(A) Cell secretion assay (B) Dynamic mass  
redistribution assay
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